Johanna Breilmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Johanna Breilmann has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Markus Koesters
University Hospital Carl Gustav Carus, TU Dresden
8 shared publications - Steffi Gerlinde Riedel-Heller
University of Leipzig
7 shared publications - Uta Gühne
Universität Leipzig
7 shared publications Andreas Küthmann
District Hospital Memmingen
5 shared publicationsBertram Schneeweiß
Kbo-Isar-Amper Hospital
5 shared publicationsPeter Brieger
Kbo-Isar-Amper Hospital
5 shared publications
Latest Publications
- 1 July 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-15
Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional Study
Severe mental illness (SMI) is frequently accompanied by substantial impairments in psychosocial functioning. Psychosocial interventions (PSI), therefore, represent an essential component of evidence-based treatment. A key prerequisite for the utilization is adequate knowledge. The aim of this study was to assess the level of knowledge about PSI among individuals with SMI. A cross-sectional multicenter study was conducted among individuals with SMI aged 18 to 65 years (n = 397). Knowledge of PSI, along with sociodemographic, clinical and additional contextual characteristics was assessed. Linear regression analyses were performed to examine associations between PSI knowledge and potential predictors. Overall, participants with SMI were familiar with an average of 10 out of the 17 assessed interventions. Better knowledge was associated with the presence of a chronic physical illness (p = .027), a longer duration of psychiatric problems (p = .030) and higher GAF scores (p = .010). In contrast, having experienced divorce, separation, or widowhood compared to being single (p = .040), as well as having a migration background (p = .003), were associated with lower levels of knowledge. The findings highlight the need for more targeted dissemination of guideline-based information on PSI to individuals with SMI.
- 1 July 2026
- Published by Springer Nature in Community Mental Health Journal
- p. 1-15
Knowledge About Psychosocial Interventions Among Individuals With Severe Mental Illness: Results of a Cross-Sectional Study
Severe mental illness (SMI) is frequently accompanied by substantial impairments in psychosocial functioning. Psychosocial interventions (PSI), therefore, represent an essential component of evidence-based treatment. A key prerequisite for the utilization is adequate knowledge. The aim of this study was to assess the level of knowledge about PSI among individuals with SMI. A cross-sectional multicenter study was conducted among individuals with SMI aged 18 to 65 years (n = 397). Knowledge of PSI, along with sociodemographic, clinical and additional contextual characteristics was assessed. Linear regression analyses were performed to examine associations between PSI knowledge and potential predictors. Overall, participants with SMI were familiar with an average of 10 out of the 17 assessed interventions. Better knowledge was associated with the presence of a chronic physical illness (p = .027), a longer duration of psychiatric problems (p = .030) and higher GAF scores (p = .010). In contrast, having experienced divorce, separation, or widowhood compared to being single (p = .040), as well as having a migration background (p = .003), were associated with lower levels of knowledge. The findings highlight the need for more targeted dissemination of guideline-based information on PSI to individuals with SMI.
- Open Access
- 23 October 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-22
Implementation of a patient-focused psychosocial intervention guideline for people with severe mental illness: Cluster-randomised controlled trial
Background: Psychosocial interventions are vital in treating severe mental illness, yet their use remains limited, and patients often lack adequate information about them. Patient-focused versions of clinical guidelines are designed to enhance mental health literacy and inform patients about available treatments, but these resources are underutilized. This study evaluated the impact of implementing a patient-focused psychosocial intervention guideline on empowerment, knowledge, and use of psychosocial interventions among individuals with severe mental illness. Methods: Multicentre, cluster-randomised trial. The study population comprised adult patients with a severe mental disorder. The intervention group received a multimodal, structured, and protocol-led patient-focused guideline implementation, whereas the control group received treatment as usual. Data were analysed using hierarchical linear models. The primary outcome was the change in patients’ empowerment. Results: There was no significant intervention effect on empowerment (effect size=0.13, p=0.605), which increased slightly in both groups. The number of psychosocial interventions familiar to patients increased significantly more in the intervention group. Exploratory analyses suggest that patient empowerment could have been influenced by COVID-19-related stress, patient age, the severity of functional impairment, and migration background. The improvement in the utilisation of psychosocial interventions did not differ significantly between the intervention group (M=1.1, SD=2.5) and the control group (M=1.3, SD=2.4). Conclusions: The implementation of a patient-focused psychosocial intervention guideline failed to enhance empowerment among service users. However, our analyses indicate that the intervention led to an improvement in patient knowledge with respect to guideline content. The availability of psychosocial interventions may have been significantly constrained by the COVID-19 pandemic.
- 23 October 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-22
Open AccessImplementation of a patient-focused psychosocial intervention guideline for people with severe mental illness: Cluster-randomised controlled trial
Background: Psychosocial interventions are vital in treating severe mental illness, yet their use remains limited, and patients often lack adequate information about them. Patient-focused versions of clinical guidelines are designed to enhance mental health literacy and inform patients about available treatments, but these resources are underutilized. This study evaluated the impact of implementing a patient-focused psychosocial intervention guideline on empowerment, knowledge, and use of psychosocial interventions among individuals with severe mental illness. Methods: Multicentre, cluster-randomised trial. The study population comprised adult patients with a severe mental disorder. The intervention group received a multimodal, structured, and protocol-led patient-focused guideline implementation, whereas the control group received treatment as usual. Data were analysed using hierarchical linear models. The primary outcome was the change in patients’ empowerment. Results: There was no significant intervention effect on empowerment (effect size=0.13, p=0.605), which increased slightly in both groups. The number of psychosocial interventions familiar to patients increased significantly more in the intervention group. Exploratory analyses suggest that patient empowerment could have been influenced by COVID-19-related stress, patient age, the severity of functional impairment, and migration background. The improvement in the utilisation of psychosocial interventions did not differ significantly between the intervention group (M=1.1, SD=2.5) and the control group (M=1.3, SD=2.4). Conclusions: The implementation of a patient-focused psychosocial intervention guideline failed to enhance empowerment among service users. However, our analyses indicate that the intervention led to an improvement in patient knowledge with respect to guideline content. The availability of psychosocial interventions may have been significantly constrained by the COVID-19 pandemic.
- 8 November 2024
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 52 (02) , 80-88
Wohnsituation von Menschen mit schweren psychischen Erkrankungen
Zusammenfassung: Ziel der Studie Psychisch erkrankte Menschen sollten selbstbestimmt in der Gemeinde wohnen, es findet sich starke Evidenz für diese Wohnform. In dieser Arbeit wurden die Wohnsituation von Menschen mit schweren psychischen Erkrankungen, die Inanspruchnahme und der Bedarf an Versorgungsangeboten analysiert. Methodik Es wurden Daten einer Querschnittsstudie mit 397 Menschen mit schweren psychischen Erkrankungen aus zwei bayerischen Bezirken verwendet und deskriptiv ausgewertet. Ergebnisse 70% der Betroffenen wohnen eigenständig. 6% leben im ambulant oder stationär betreuten Wohnen. 25% der Betroffenen sind auf Hilfe beim Wohnen angewiesen, wobei 39% hiervon nicht die nötige Hilfe erhalten. Die betreuenden Wohnformen sind den meisten Betroffenen bekannt und wurden als hilfreich empfunden. Schlussfolgerung Die meisten Betroffenen leben in einer der gesellschaftlichen Norm entsprechenden Wohnsituation. Dennoch besteht bei einem Teil der Betroffenen ein ungelöstes Wohnproblem. Die Inanspruchnahme von ambulant oder stationär betreutem Wohnen ist hilfreich, die Unterstützung wird aber kaum genutzt.
- 8 November 2024
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 52 (02) , 80-88
Wohnsituation von Menschen mit schweren psychischen Erkrankungen
Zusammenfassung: Ziel der Studie Psychisch erkrankte Menschen sollten selbstbestimmt in der Gemeinde wohnen, es findet sich starke Evidenz für diese Wohnform. In dieser Arbeit wurden die Wohnsituation von Menschen mit schweren psychischen Erkrankungen, die Inanspruchnahme und der Bedarf an Versorgungsangeboten analysiert. Methodik Es wurden Daten einer Querschnittsstudie mit 397 Menschen mit schweren psychischen Erkrankungen aus zwei bayerischen Bezirken verwendet und deskriptiv ausgewertet. Ergebnisse 70% der Betroffenen wohnen eigenständig. 6% leben im ambulant oder stationär betreuten Wohnen. 25% der Betroffenen sind auf Hilfe beim Wohnen angewiesen, wobei 39% hiervon nicht die nötige Hilfe erhalten. Die betreuenden Wohnformen sind den meisten Betroffenen bekannt und wurden als hilfreich empfunden. Schlussfolgerung Die meisten Betroffenen leben in einer der gesellschaftlichen Norm entsprechenden Wohnsituation. Dennoch besteht bei einem Teil der Betroffenen ein ungelöstes Wohnproblem. Die Inanspruchnahme von ambulant oder stationär betreutem Wohnen ist hilfreich, die Unterstützung wird aber kaum genutzt.
- 22 October 2024
- Published by Springer Nature in Der Nervenarzt
- Vol. 96 (1) , 57-65
Selbsthilfeangebote für Menschen mit schwerer psychischer Erkrankung – wer nutzt welches Format?
Zusammenfassung Hintergrund Selbsthilfe kann eine wichtige ergänzende Rolle in der Behandlung schwer psychisch erkrankter Menschen spielen. Allerdings ist wenig über die Nutzung der verschiedenen Ansätze bekannt. Ziel der Arbeit Im Beitrag wird die Nutzung verschiedener Selbsthilfemöglichkeiten bei Patient:innen mit schweren psychischen Erkrankungen beschrieben. Mögliche Prädiktoren werden untersucht. Material und Methoden Im Rahmen einer Querschnittsstudie (IMPPETUS, N = 397) wurden zwischen März und September 2019 soziodemografische sowie krankheits- und behandlungsassoziierte Daten erhoben. Mittels binärer logistischer Regressionen wurde ein möglicher Zusammenhang mit der Nutzung von Selbsthilfe analysiert. Ergebnisse Am häufigsten angegeben wurde die Nutzung von Ratgeberliteratur (n = 170; 45,5 %), gefolgt von Selbsthilfegruppen (n = 130; 33,2 %), E‑Mental-Health-Angeboten (n = 56; 15,5 %) und Selbstmanagementansätzen (n = 54; 14,8 %). Trialogforen (n = 36; 9,9 %) wurden von den Teilnehmenden am wenigsten genutzt. Die Nutzung der verschiedenen Ansätze wird durch soziodemografische und krankheitsassoziierte Merkmale (Alter, Bildung, Familienstand, Migrationshintergrund, Alter bei Auftreten erster psychischer Probleme, psychosoziales Funktionsniveau), nicht aber durch behandlungsassoziierte Merkmale beeinflusst. Schlussfolgerung Das Potenzial von Selbsthilfe wird in der untersuchten Stichprobe nicht annähernd ausgeschöpft. Die Nutzung der verschiedenen Selbsthilfemöglichkeiten durch die Teilnehmenden schwankt zwischen etwa 10 und 46 %. Dabei werden von den unterschiedlichen Formaten spezifische Zielgruppen angesprochen. Um das Selbsthilfepotenzial stärker nutzbar zu machen, muss gezielter als bisher über die verschiedenen Möglichkeiten informiert und die Nutzung von Selbsthilfe im Behandlungsalltag aktiv unterstützt werden.
- 22 October 2024
- Published by Springer Nature in Der Nervenarzt
- Vol. 96 (1) , 57-65
Selbsthilfeangebote für Menschen mit schwerer psychischer Erkrankung – wer nutzt welches Format?
Zusammenfassung Hintergrund Selbsthilfe kann eine wichtige ergänzende Rolle in der Behandlung schwer psychisch erkrankter Menschen spielen. Allerdings ist wenig über die Nutzung der verschiedenen Ansätze bekannt. Ziel der Arbeit Im Beitrag wird die Nutzung verschiedener Selbsthilfemöglichkeiten bei Patient:innen mit schweren psychischen Erkrankungen beschrieben. Mögliche Prädiktoren werden untersucht. Material und Methoden Im Rahmen einer Querschnittsstudie (IMPPETUS, N = 397) wurden zwischen März und September 2019 soziodemografische sowie krankheits- und behandlungsassoziierte Daten erhoben. Mittels binärer logistischer Regressionen wurde ein möglicher Zusammenhang mit der Nutzung von Selbsthilfe analysiert. Ergebnisse Am häufigsten angegeben wurde die Nutzung von Ratgeberliteratur (n = 170; 45,5 %), gefolgt von Selbsthilfegruppen (n = 130; 33,2 %), E‑Mental-Health-Angeboten (n = 56; 15,5 %) und Selbstmanagementansätzen (n = 54; 14,8 %). Trialogforen (n = 36; 9,9 %) wurden von den Teilnehmenden am wenigsten genutzt. Die Nutzung der verschiedenen Ansätze wird durch soziodemografische und krankheitsassoziierte Merkmale (Alter, Bildung, Familienstand, Migrationshintergrund, Alter bei Auftreten erster psychischer Probleme, psychosoziales Funktionsniveau), nicht aber durch behandlungsassoziierte Merkmale beeinflusst. Schlussfolgerung Das Potenzial von Selbsthilfe wird in der untersuchten Stichprobe nicht annähernd ausgeschöpft. Die Nutzung der verschiedenen Selbsthilfemöglichkeiten durch die Teilnehmenden schwankt zwischen etwa 10 und 46 %. Dabei werden von den unterschiedlichen Formaten spezifische Zielgruppen angesprochen. Um das Selbsthilfepotenzial stärker nutzbar zu machen, muss gezielter als bisher über die verschiedenen Möglichkeiten informiert und die Nutzung von Selbsthilfe im Behandlungsalltag aktiv unterstützt werden.
- 9 October 2023
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 51 (03) , 129-138
Einfluss von Leitlinienempfehlungen, Versorgungsstrukturen und individuellen Faktoren auf die Inanspruchnahme von psychosozialen Therapien bei schwer psychisch kranken Menschen
Zusammenfassung: Ziel der Studie Der Einfluss von Leitlinien-Empfehlungen und weiterer Faktoren auf die Inanspruchnahme von psychosozialen Therapien bei Menschen mit schweren psychischen Erkrankungen wurde untersucht. Methodik Es wurden Daten einer Querschnittsstudie mit 397 Personen mit schweren psychischen Erkrankungen deskriptiv analysiert. Ergebnisse Betroffene erhalten seltener Therapien mit einer starken Empfehlung im Vergleich zu anderen Empfehlungsgraden. Verschiedene weitere Faktoren sind diffus mit den Inanspruchnahmeraten assoziiert, es konnte jedoch kein ubiquitärer Einflussfaktor über alle Therapien hinweg identifiziert werden. Schlussfolgerung Die aktuelle Praxis beim Einsatz psychosozialer Therapien folgt nicht den Empfehlungsstärken der S3-Leitlinie. Interventionen mit starken Empfehlungen stehen vermutlich nicht ausreichend zur Verfügung, weshalb die Routinepraxis demzufolge nicht in der Lage ist, Leitlinienempfehlungen entsprechend ihrer Stärke zu folgen. Andere einheitliche Prädiktoren konnten nicht identifiziert werden.
- 9 October 2023
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 51 (03) , 129-138
Einfluss von Leitlinienempfehlungen, Versorgungsstrukturen und individuellen Faktoren auf die Inanspruchnahme von psychosozialen Therapien bei schwer psychisch kranken Menschen
Zusammenfassung: Ziel der Studie Der Einfluss von Leitlinien-Empfehlungen und weiterer Faktoren auf die Inanspruchnahme von psychosozialen Therapien bei Menschen mit schweren psychischen Erkrankungen wurde untersucht. Methodik Es wurden Daten einer Querschnittsstudie mit 397 Personen mit schweren psychischen Erkrankungen deskriptiv analysiert. Ergebnisse Betroffene erhalten seltener Therapien mit einer starken Empfehlung im Vergleich zu anderen Empfehlungsgraden. Verschiedene weitere Faktoren sind diffus mit den Inanspruchnahmeraten assoziiert, es konnte jedoch kein ubiquitärer Einflussfaktor über alle Therapien hinweg identifiziert werden. Schlussfolgerung Die aktuelle Praxis beim Einsatz psychosozialer Therapien folgt nicht den Empfehlungsstärken der S3-Leitlinie. Interventionen mit starken Empfehlungen stehen vermutlich nicht ausreichend zur Verfügung, weshalb die Routinepraxis demzufolge nicht in der Lage ist, Leitlinienempfehlungen entsprechend ihrer Stärke zu folgen. Andere einheitliche Prädiktoren konnten nicht identifiziert werden.
- Open Access
- 15 February 2022
- Published by Springer Nature in BMC Psychiatry
- Vol. 22 (1) , 1-13
The role of migration in mental healthcare: treatment satisfaction and utilization
Migration rates increase globally and require an adaption of national mental health services to the needs of persons with migration background. Therefore, we aimed to identify differences between persons with and without migratory background regarding (1) treatment satisfaction, (2) needed and received mental healthcare and (3) utilization of mental healthcare.In the context of a cross-sectional multicenter study, inpatients and day hospital patients of psychiatric settings in Southern Germany with severe affective and non-affective psychoses were included. Patients’ satisfaction with and their use of mental healthcare services were assessed by VSSS-54 and CSSRI-EU; patients’ needs were measured via CAN-EU.In total, 387 participants (migratory background: n = 72; 19%) provided sufficient responses for analyses. Migrant patients were more satisfied with the overall treatment in the past year compared to non-migrant patients. No differences between both groups were identified in met and unmet treatment needs and use of supply services (psychiatric, psychotherapeutic, and psychosocial treatment).Despite a comparable degree of met and unmet treatment needs and mental health service use among migrants and non-migrants, patients with migration background showed higher overall treatment satisfaction compared to non-migrants. The role of sociocultural and migrant-related factors may explain our findings.
- 15 February 2022
- Published by Springer Nature in BMC Psychiatry
- Vol. 22 (1) , 1-13
Open AccessThe role of migration in mental healthcare: treatment satisfaction and utilization
Migration rates increase globally and require an adaption of national mental health services to the needs of persons with migration background. Therefore, we aimed to identify differences between persons with and without migratory background regarding (1) treatment satisfaction, (2) needed and received mental healthcare and (3) utilization of mental healthcare.In the context of a cross-sectional multicenter study, inpatients and day hospital patients of psychiatric settings in Southern Germany with severe affective and non-affective psychoses were included. Patients’ satisfaction with and their use of mental healthcare services were assessed by VSSS-54 and CSSRI-EU; patients’ needs were measured via CAN-EU.In total, 387 participants (migratory background: n = 72; 19%) provided sufficient responses for analyses. Migrant patients were more satisfied with the overall treatment in the past year compared to non-migrant patients. No differences between both groups were identified in met and unmet treatment needs and use of supply services (psychiatric, psychotherapeutic, and psychosocial treatment).Despite a comparable degree of met and unmet treatment needs and mental health service use among migrants and non-migrants, patients with migration background showed higher overall treatment satisfaction compared to non-migrants. The role of sociocultural and migrant-related factors may explain our findings.
- 16 June 2021
- Published by Georg Thieme Verlag KG in Aktuelle Ernahrungsmedizin
- Vol. 46 (03) , PP-33
ERNÄHRUNG VON MENSCHEN MIT PSYCHISCHEN ERKRANKUNGEN – EIN NEUES FELD DER ERNÄHRUNGSMEDIZIN
Introduction Die 12-Monatsprävalenz für psychische Erkrankungen beträgt 27,5 % in der erwachsenen Allgemeinbevölkerung. Menschen mit schweren psychischen Erkrankungen leiden häufig zusätzlich an somatischen Komorbiditäten und damit geht eine um 10 bis 20 Jahre reduzierte Lebenserwartung einher. Außer den Nebenwirkungen von Medikamenten und der Vernachlässigung körperlicher Symptome in der ärztlichen Behandlung bilden ungünstige Lebensstilfaktoren hierfür eine zentrale Ursache. Objectives In diesem Beitrag soll das junge Forschungsfeld der ‘Nutritional Psychiatry Research’ anhand von Fallstudien vorgestellt werden. Methods Im Rahmen einer DFG-Förderung zur Initiierung internationaler Kooperationen wurden zwischenzeitig verschiedene systematische Reviews initiiert und durchgeführt. Des Weiteren wurden qualitative Leitfadeninterviews mit Menschen mit psychischen Erkrankungen in Deutschland, Österreich und Australien durchgeführt und analysiert. Results Die ersten Ergebnisse weisen darauf hin, dass viele Menschen mit psychischen Erkrankungen ein ungesundes bzw. gestörtes Ernährungsverhalten aufzeigen. Die Betroffenen sehen die Ursachen hierfür teils in ihrem psychischen Gesundheitszustand bzw. ihrer medikamentösen Behandlung. Der Wunsch nach mehr Unterstützung zur Verbesserung des Ernährungsverhaltens im Rahmen der psychiatrischen Versorgung wurde mehrfach geäußert. Evidenzbasierte Empfehlungen bzw. strukturierte Programme für diese Zielgruppe existieren bislang kaum in Deutschland. Conclusion Die S3-Leitlinie ‘Psychosoziale Therapien bei schweren psychischen Erkrankungen’ gibt die Empfehlung, ernährungsbezogene Maßnahmen zur Gesundheitsförderung in dieser Zielgruppe einzusetzen. Als Voraussetzung müssen jedoch entsprechende Programme zuerst noch mit Betroffenen entwickelt und auf deren Wirksamkeit untersucht werden. Gute Grundlagen bilden hierfür internationale Modellprojekte und erste Erkenntnisse aus deutschen Pilotstudien. Disclosure of Interest None declared Publication Date: 16 June 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 16 June 2021
- Published by Georg Thieme Verlag KG in Aktuelle Ernahrungsmedizin
- Vol. 46 (03) , PP-33
ERNÄHRUNG VON MENSCHEN MIT PSYCHISCHEN ERKRANKUNGEN – EIN NEUES FELD DER ERNÄHRUNGSMEDIZIN
Introduction Die 12-Monatsprävalenz für psychische Erkrankungen beträgt 27,5 % in der erwachsenen Allgemeinbevölkerung. Menschen mit schweren psychischen Erkrankungen leiden häufig zusätzlich an somatischen Komorbiditäten und damit geht eine um 10 bis 20 Jahre reduzierte Lebenserwartung einher. Außer den Nebenwirkungen von Medikamenten und der Vernachlässigung körperlicher Symptome in der ärztlichen Behandlung bilden ungünstige Lebensstilfaktoren hierfür eine zentrale Ursache. Objectives In diesem Beitrag soll das junge Forschungsfeld der ‘Nutritional Psychiatry Research’ anhand von Fallstudien vorgestellt werden. Methods Im Rahmen einer DFG-Förderung zur Initiierung internationaler Kooperationen wurden zwischenzeitig verschiedene systematische Reviews initiiert und durchgeführt. Des Weiteren wurden qualitative Leitfadeninterviews mit Menschen mit psychischen Erkrankungen in Deutschland, Österreich und Australien durchgeführt und analysiert. Results Die ersten Ergebnisse weisen darauf hin, dass viele Menschen mit psychischen Erkrankungen ein ungesundes bzw. gestörtes Ernährungsverhalten aufzeigen. Die Betroffenen sehen die Ursachen hierfür teils in ihrem psychischen Gesundheitszustand bzw. ihrer medikamentösen Behandlung. Der Wunsch nach mehr Unterstützung zur Verbesserung des Ernährungsverhaltens im Rahmen der psychiatrischen Versorgung wurde mehrfach geäußert. Evidenzbasierte Empfehlungen bzw. strukturierte Programme für diese Zielgruppe existieren bislang kaum in Deutschland. Conclusion Die S3-Leitlinie ‘Psychosoziale Therapien bei schweren psychischen Erkrankungen’ gibt die Empfehlung, ernährungsbezogene Maßnahmen zur Gesundheitsförderung in dieser Zielgruppe einzusetzen. Als Voraussetzung müssen jedoch entsprechende Programme zuerst noch mit Betroffenen entwickelt und auf deren Wirksamkeit untersucht werden. Gute Grundlagen bilden hierfür internationale Modellprojekte und erste Erkenntnisse aus deutschen Pilotstudien. Disclosure of Interest None declared Publication Date: 16 June 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 4 March 2021
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 144 (2) , 113-124
Systematic evaluation of the ‘efficacy‐effectiveness gap’ in the treatment of depression with venlafaxine and duloxetine
Objective Evidence of larger drug effects in highly standardized studies (efficacy) compared to clinical routine (effectiveness) is discussed as efficacy‐effectiveness gap. This study aimed to quantify effect size differences of RCTs and non‐RCTs in the treatment of depression with venlafaxine and duloxetine and to identify effect modifying predictors. Methods A comprehensive systematic review and meta‐analysis was conducted, including all prospective trials, which evaluated the treatment effects of duloxetine or venlafaxine in patients with depression. The primary outcome was the pre‐post effect size after acute therapy, which were compared between RCTs and non‐RCTs. Moreover, an exploratory analysis of predictors in a mixed meta‐regression model within an information‐theoretic approach was performed. Results 171 RCTs and 74 non‐RCTs were included. The pre‐post effect size differed significantly between RCTs and non‐RCTs (−3.04 vs. −2.62, Δ = 0.41, p = 0.012, high heterogeneity). Study characteristics were very similar between RCTs and non‐RCTs. Most important variables to predict effect sizes were ‘depression severity’, ‘dose’ and ‘number of participants’. Conclusion Despite differences in effect sizes between RCTs and non‐RCTs, study design is not clearly an important predictor for the effect sizes. Our results question the common assumption that non‐RCTs are generally better suited to describe a drug’s effectiveness in clinical practice than RCTs. Future studies and their reporting should put more emphasis on the description of external validity, in order to allow better assessments of clinical relevance.
- 4 March 2021
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 144 (2) , 113-124
Open AccessSystematic evaluation of the ‘efficacy‐effectiveness gap’ in the treatment of depression with venlafaxine and duloxetine
Objective Evidence of larger drug effects in highly standardized studies (efficacy) compared to clinical routine (effectiveness) is discussed as efficacy‐effectiveness gap. This study aimed to quantify effect size differences of RCTs and non‐RCTs in the treatment of depression with venlafaxine and duloxetine and to identify effect modifying predictors. Methods A comprehensive systematic review and meta‐analysis was conducted, including all prospective trials, which evaluated the treatment effects of duloxetine or venlafaxine in patients with depression. The primary outcome was the pre‐post effect size after acute therapy, which were compared between RCTs and non‐RCTs. Moreover, an exploratory analysis of predictors in a mixed meta‐regression model within an information‐theoretic approach was performed. Results 171 RCTs and 74 non‐RCTs were included. The pre‐post effect size differed significantly between RCTs and non‐RCTs (−3.04 vs. −2.62, Δ = 0.41, p = 0.012, high heterogeneity). Study characteristics were very similar between RCTs and non‐RCTs. Most important variables to predict effect sizes were ‘depression severity’, ‘dose’ and ‘number of participants’. Conclusion Despite differences in effect sizes between RCTs and non‐RCTs, study design is not clearly an important predictor for the effect sizes. Our results question the common assumption that non‐RCTs are generally better suited to describe a drug’s effectiveness in clinical practice than RCTs. Future studies and their reporting should put more emphasis on the description of external validity, in order to allow better assessments of clinical relevance.
- Open Access
- 18 March 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-10
Implementation of the patient version of the evidence-based (S3) guideline for psychosocial interventions for patients with severe mental illness (IMPPETUS): study protocol for a cluster randomised controlled trial
Background: The German guideline on psychosocial interventions for people with severe mental disorders recommends a broad spectrum of evidence-based treatments. Structured implementation of the associated patient version of the guideline is missing to date. The study aims to assess whether structured implementation of a patient guideline improves the empowerment of patients with severe mental disorders, as well as knowledge, attitudes and experiences regarding psychosocial interventions, service use, treatment satisfaction, treatment needs, quality of life and burden of care. Methods: The study is a multicentre, cluster-randomised, controlled study with two parallel groups. Inpatients and day hospital patients (all sexes; 18–65 years) with severe mental disorders will be included. Additionally, relatives of patients with mental disorders (all sexes; ≥ 18 years) will be included. In the experimental group, the patient guideline will be implemented using a multimodal strategy. Participants in the control group will receive treatment as usual but will be made aware of the patient guideline. The primary outcome is the change of empowerment, assessed by using the ‘empowerment in the process of psychiatric treatment of patients with affective and schizophrenia disorders’ (EPAS) scale. In addition, knowledge, attitudes and experiences regarding psychosocial interventions will be assessed as secondary outcomes, as well as service use, satisfaction with care, patient need and quality of life and participation and social inclusion. For relatives, the perceived burden of care also will be recorded. Results will be analysed using hierarchical linear models. For the health economic evaluation, the incremental cost-utility ratios will be computed using the differences in total costs of illness and the differences in quality-adjusted life years (QALY) between study groups. Discussion: The study will be the first to assess the effects of a structured implementation of the patient version of a psychiatric treatment guideline. The study has some limitations regarding the transferability of the results to other patients and other regions. Furthermore, problems with the recruitment of patients and relatives and with the implementation of intervention could occur during the study. Trial registration: The study is registered in the German Clinical Trials Register (DRKS) and the WHO International Clinical Trials Registry Platform (ICTRP) under registration number DRKS00017577 (Date of registration: 23 October 2019.
- 18 March 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-10
Open AccessImplementation of the patient version of the evidence-based (S3) guideline for psychosocial interventions for patients with severe mental illness (IMPPETUS): study protocol for a cluster randomised controlled trial
Background: The German guideline on psychosocial interventions for people with severe mental disorders recommends a broad spectrum of evidence-based treatments. Structured implementation of the associated patient version of the guideline is missing to date. The study aims to assess whether structured implementation of a patient guideline improves the empowerment of patients with severe mental disorders, as well as knowledge, attitudes and experiences regarding psychosocial interventions, service use, treatment satisfaction, treatment needs, quality of life and burden of care. Methods: The study is a multicentre, cluster-randomised, controlled study with two parallel groups. Inpatients and day hospital patients (all sexes; 18–65 years) with severe mental disorders will be included. Additionally, relatives of patients with mental disorders (all sexes; ≥ 18 years) will be included. In the experimental group, the patient guideline will be implemented using a multimodal strategy. Participants in the control group will receive treatment as usual but will be made aware of the patient guideline. The primary outcome is the change of empowerment, assessed by using the ‘empowerment in the process of psychiatric treatment of patients with affective and schizophrenia disorders’ (EPAS) scale. In addition, knowledge, attitudes and experiences regarding psychosocial interventions will be assessed as secondary outcomes, as well as service use, satisfaction with care, patient need and quality of life and participation and social inclusion. For relatives, the perceived burden of care also will be recorded. Results will be analysed using hierarchical linear models. For the health economic evaluation, the incremental cost-utility ratios will be computed using the differences in total costs of illness and the differences in quality-adjusted life years (QALY) between study groups. Discussion: The study will be the first to assess the effects of a structured implementation of the patient version of a psychiatric treatment guideline. The study has some limitations regarding the transferability of the results to other patients and other regions. Furthermore, problems with the recruitment of patients and relatives and with the implementation of intervention could occur during the study. Trial registration: The study is registered in the German Clinical Trials Register (DRKS) and the WHO International Clinical Trials Registry Platform (ICTRP) under registration number DRKS00017577 (Date of registration: 23 October 2019.
- 28 March 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 3 (3) , CD010677
Benzodiazepines versus placebo for panic disorder in adults
Background Panic disorder is characterised by recurrent unexpected panic attacks consisting of a wave of intense fear that reaches a peak within a few minutes. Panic disorder is a common disorder, with an estimated lifetime prevalence of 1% to 5% in the general population and a 7% to 10% prevalence in primary care settings. Its aetiology is not fully understood and is probably heterogeneous. Panic disorder is treated with psychological and pharmacological interventions, often used in combination. Although benzodiazepines are frequently used in the treatment of panic disorder, guidelines recommend antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), as first‐line treatment for panic disorder, particularly due to their lower incidence of dependence and withdrawal reaction when compared to benzodiazepines. Despite these recommendations, benzodiazepines are widely used in the treatment of panic disorder, probably because of their rapid onset of action. Objectives To assess the efficacy and acceptability of benzodiazepines versus placebo in the treatment of panic disorder with or without agoraphobia in adults. Search methods We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR Studies and References), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950‐), Embase (1974‐), and PsycINFO (1967‐) up to 29 May 2018. We handsearched reference lists of relevant papers and previous systematic reviews. We contacted experts in the field for supplemental data. Selection criteria All double‐blind (blinding of patients and personnel) controlled trials randomising adults with panic disorder with or without agoraphobia to benzodiazepine or placebo. Data collection and analysis Two review authors independently checked the eligibility of studies and extracted data using a standardised form. Data were then entered data into Review Manager 5 using a double‐check procedure. Information extracted included study characteristics, participant characteristics, intervention details, settings, and outcome measures in terms of efficacy, acceptability, and tolerability. Main results We included 24 studies in the review with a total of 4233 participants, of which 2124 were randomised to benzodiazepines and 1475 to placebo. The remaining 634 participants were randomised to other active treatments in three‐arm trials. We assessed the overall methodological quality of the included studies as poor. We rated all studies as at unclear risk of bias in at least three domains. In addition, we judged 20 of the 24 included studies as having a high risk of bias in at least one domain. Two primary outcomes of efficacy and acceptability showed a possible advantage of benzodiazepines over placebo. The estimated risk ratio (RR) for a response to treatment was 1.65 (95% confidence interval (CI) 1.39 to 1.96) in favour of benzodiazepines, which corresponds to an estimated number needed to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to 7). The dropout rate was lower among participants treated with benzodiazepines (RR 0.50, 95% CI 0.39 to 0.64); the estimated NNTB was 6 (95% CI 5 to 9). We rated the quality of the evidence as low for both primary outcomes. The possible advantage of benzodiazepine was also seen for remission (RR 1.61, 95% CI 1.38 to 1.88) and the endpoint data for social functioning (standardised mean difference (SMD) ‐0.53, 95% CI ‐0.65 to ‐0.42), both with low‐quality evidence. We assessed the evidence for the other secondary outcomes as of very low quality. With the exception of the analyses of the change score data for depression (SMD ‐0.22, 95% CI ‐0.48 to 0.04) and social functioning (SMD ‐0.32, 95% CI ‐0.88 to 0.24), all secondary outcome analyses showed an effect in favour of benzodiazepines compared to placebo. However, the number of dropouts due to adverse effects was higher with benzodiazepines than with placebo (RR 1.58, 95% CI 1.16 to 2.15; low‐quality evidence). Furthermore, our analyses of adverse events showed that a higher proportion of participants experienced at least one adverse effect when treated with benzodiazepines (RR 1.18, 95% CI 1.02 to 1.37; low‐quality evidence). Authors' conclusions Low‐quality evidence shows a possible superiority of benzodiazepine over placebo in the short‐term treatment of panic disorders. The validity of the included studies is questionable due to possible unmasking of allocated treatments, high dropout rates, and probable publication bias. Moreover, the included studies were only short‐term studies and did not examine the long‐term efficacy nor the risks of dependency and withdrawal symptoms. Due to these limitations, our results regarding the efficacy of benzodiazepines versus placebo provide only limited guidance for clinical practice. Furthermore, the clinician's choice is not between benzodiazepines and placebo, but between benzodiazepines and other agents, notably SSRIs, both in terms of efficacy and adverse effects. The choice of treatment should therefore be guided by the patient's preference and should balance benefits and harms from treatment in a long‐term perspective.
- 28 March 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 3 (3) , CD010677
Benzodiazepines versus placebo for panic disorder in adults
Background Panic disorder is characterised by recurrent unexpected panic attacks consisting of a wave of intense fear that reaches a peak within a few minutes. Panic disorder is a common disorder, with an estimated lifetime prevalence of 1% to 5% in the general population and a 7% to 10% prevalence in primary care settings. Its aetiology is not fully understood and is probably heterogeneous. Panic disorder is treated with psychological and pharmacological interventions, often used in combination. Although benzodiazepines are frequently used in the treatment of panic disorder, guidelines recommend antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), as first‐line treatment for panic disorder, particularly due to their lower incidence of dependence and withdrawal reaction when compared to benzodiazepines. Despite these recommendations, benzodiazepines are widely used in the treatment of panic disorder, probably because of their rapid onset of action. Objectives To assess the efficacy and acceptability of benzodiazepines versus placebo in the treatment of panic disorder with or without agoraphobia in adults. Search methods We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR Studies and References), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1950‐), Embase (1974‐), and PsycINFO (1967‐) up to 29 May 2018. We handsearched reference lists of relevant papers and previous systematic reviews. We contacted experts in the field for supplemental data. Selection criteria All double‐blind (blinding of patients and personnel) controlled trials randomising adults with panic disorder with or without agoraphobia to benzodiazepine or placebo. Data collection and analysis Two review authors independently checked the eligibility of studies and extracted data using a standardised form. Data were then entered data into Review Manager 5 using a double‐check procedure. Information extracted included study characteristics, participant characteristics, intervention details, settings, and outcome measures in terms of efficacy, acceptability, and tolerability. Main results We included 24 studies in the review with a total of 4233 participants, of which 2124 were randomised to benzodiazepines and 1475 to placebo. The remaining 634 participants were randomised to other active treatments in three‐arm trials. We assessed the overall methodological quality of the included studies as poor. We rated all studies as at unclear risk of bias in at least three domains. In addition, we judged 20 of the 24 included studies as having a high risk of bias in at least one domain. Two primary outcomes of efficacy and acceptability showed a possible advantage of benzodiazepines over placebo. The estimated risk ratio (RR) for a response to treatment was 1.65 (95% confidence interval (CI) 1.39 to 1.96) in favour of benzodiazepines, which corresponds to an estimated number needed to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to 7). The dropout rate was lower among participants treated with benzodiazepines (RR 0.50, 95% CI 0.39 to 0.64); the estimated NNTB was 6 (95% CI 5 to 9). We rated the quality of the evidence as low for both primary outcomes. The possible advantage of benzodiazepine was also seen for remission (RR 1.61, 95% CI 1.38 to 1.88) and the endpoint data for social functioning (standardised mean difference (SMD) ‐0.53, 95% CI ‐0.65 to ‐0.42), both with low‐quality evidence. We assessed the evidence for the other secondary outcomes as of very low quality. With the exception of the analyses of the change score data for depression (SMD ‐0.22, 95% CI ‐0.48 to 0.04) and social functioning (SMD ‐0.32, 95% CI ‐0.88 to 0.24), all secondary outcome analyses showed an effect in favour of benzodiazepines compared to placebo. However, the number of dropouts due to adverse effects was higher with benzodiazepines than with placebo (RR 1.58, 95% CI 1.16 to 2.15; low‐quality evidence). Furthermore, our analyses of adverse events showed that a higher proportion of participants experienced at least one adverse effect when treated with benzodiazepines (RR 1.18, 95% CI 1.02 to 1.37; low‐quality evidence). Authors' conclusions Low‐quality evidence shows a possible superiority of benzodiazepine over placebo in the short‐term treatment of panic disorders. The validity of the included studies is questionable due to possible unmasking of allocated treatments, high dropout rates, and probable publication bias. Moreover, the included studies were only short‐term studies and did not examine the long‐term efficacy nor the risks of dependency and withdrawal symptoms. Due to these limitations, our results regarding the efficacy of benzodiazepines versus placebo provide only limited guidance for clinical practice. Furthermore, the clinician's choice is not between benzodiazepines and placebo, but between benzodiazepines and other agents, notably SSRIs, both in terms of efficacy and adverse effects. The choice of treatment should therefore be guided by the patient's preference and should balance benefits and harms from treatment in a long‐term perspective.